Study record

Circulating levels of mitochondrial oxidative stress-related peptides MOTS-c and Romo1 in stable COPD: A cross-sectional study

Amado CA, Martín-Audera P, Agüero J et al. · Front Med (Lausanne) · 2023

Human obs.Endogenous MOTS-c measuredEvidence tier B
PubMed 36844198doi:10.3389/fmed.2023.1100211Full text (PMC)Compare with another study

What this study reported

Measured serum MOTS-c and Romo1 in adults with stable COPD and in smokers with normal lung function. Found lower serum MOTS-c and higher serum Romo1 in the COPD group than in the comparison group, and reported that below-median MOTS-c was associated with oxygen desaturation and with walking under 350 metres in the six-minute walk test, while above-median MOTS-c was associated with higher Romo1.

Limitations

Cross-sectional design with no follow-up, so temporal direction cannot be established; the comparison group of 47 smokers is much smaller than the COPD group, and MOTS-c showed no association with other COPD characteristics.

Study record

Annotated fields for this study
Study modelHuman observational
Substance studiedEndogenous MOTS-c measuredNaturally occurring MOTS-c was measured; nothing was given.
Specieshuman
System studiedPatients with stable chronic obstructive pulmonary disease and smokers with normal lung function
Populationadults with stable COPD and smokers with normal lung function
DesignCross-sectional observational cohort
Sample size as reported142 patients with stable COPD and 47 smokers with normal lung function
Control group47 smokers with normal lung function
Route (data field only)Not reported
Endpoints measuredserum MOTS-c; serum Romo1; oxygen desaturation; six-minute walk distance; current smoking status
Pathways measuredOxidative stress
Research areasLung
Evidence tierB — Other human study
Publication typesJournal Article

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Direct
Model applicability
Human
Sample size
Adequate
Controls
Limited
Outcome validity
Validated biomarker
Support for its own conclusion
Moderate

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.